PBH (Prestige Consumer Healthcare) Total Receivables: $187 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBH Prestige Consumer Healthcare Inc PBH
69 GF Score
Price $50.52
GF Value $70.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prestige Consumer Healthcare Total Receivables?

Prestige Consumer Healthcare PBH -2.24% 69 Total Receivables is $187 Mil as of Jun. 2026. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Prestige Consumer Healthcare's Total Receivables for the quarter that ended in Jun. 2026 was $187 Mil.

Prestige Consumer Healthcare Total Receivables Related Terms

Prestige Consumer Healthcare Total Receivables Historical Data

* Premium members only.

The historical data trend for Prestige Consumer Healthcare's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prestige Consumer Healthcare Total Receivables Chart

Prestige Consumer Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.33 167.02 176.78 194.29 191.92

Prestige Consumer Healthcare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.41 199.00 190.46 191.92 187.36
PBH
69GF Score
Prestige Consumer Healthcare Inc PBH
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prestige Consumer Healthcare Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $187 Mil mean?
Prestige Consumer Healthcare (PBH) has a Total Receivables of $187 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Prestige Consumer Healthcare and its competitors.
Is Prestige Consumer Healthcare's Total Receivables too high?
Prestige Consumer Healthcare's current Total Receivables is $187 Mil. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Total Receivables compare to BCRX and AMLX?
Prestige Consumer Healthcare's Total Receivables of $187 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Prestige Consumer Healthcare and its competitors. Prestige Consumer Healthcare's current Total Receivables is $187 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current Total Receivables is $187 Mil. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Total Receivables is $187 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?

Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued. The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51. GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.

Key valuation signals for PBH:

  • Total Receivables: $187 Mil
  • GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prestige Consumer Healthcare Business Description

Other Exchanges PBV:Germany
Address 660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score

Get the complete analysis for PBH

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.52
Price
$70.51
GF Value